Survivors and patient advocates to talk about the most recent science on cancer prevention.

16-19 What: The 11th Annual AACR International Conference on Frontiers in Malignancy Prevention Research will bring together scientists, survivors and patient advocates to talk about the most recent science on cancer prevention. The meeting, scheduled for Oct. 16-19, 2012, in Anaheim, Calif., will include a group of groundbreaking presentations and hundreds of new analysis abstracts including: updates from the Physician’s Health Study on multivitamins and malignancy; new data on the protecting effect of green tea; how formulation feeding affects the risk for leukemia in children; whether hay fever escalates the risk for colorectal malignancy; fresh data on chemoprevention strategies; how hormones affect breast cancer risk; updated tools for diagnosis of prostate and colon cancers; and whether monetary incentives can keep people from smoking.The probability of surviving free from disease progression for 4 years after randomization was 43 percent in the lenalidomide group, in comparison with 22 percent in the placebo group ; 79 sufferers in the lenalidomide group and 73 patients in the placebo group had passed away by October 2011 . The overall survival rate 4 years after randomization was similar in the two organizations . Salvage Therapy As of October 2011, a complete of 124 patients in the lenalidomide group had disease progression, and 108 symptomatic patients had received a second-series therapy: lenalidomide , bortezomib , thalidomide , bortezomib plus thalidomide , or chemotherapy without new agents . In the placebo group, 199 patients experienced disease progression, and 173 symptomatic patients had received a second-range therapy: lenalidomide , bortezomib , thalidomide , bortezomib plus thalidomide , or chemotherapy without brand-new brokers .